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Introduction
The myeloproliferative neoplasms (MPN), essential thrombocytosis (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) share the same acquired genetic lesion, JAK2 V617F, but differ with respect to epidemiology and natural history. PMF is the rarest of the classical MPN, has a male sex predominance, and manifests at an older age compared to ET and PV.(1, 2) PMF carries the worst prognosis due to complications of bone marrow failure or leukemic transformation. These phenotypic differences raise the question as to how a shared genetic lesion could result in three distinct disorders.
Within the JAK2 V617F-positive MPN, variation in both gene dosage of JAK2 V617F and the disease burden at the progenitor level offer some rationale as to the discrepancy between genotype and phenotype. Low JAK2 V617F allele burdens associate with ET and higher allele burdens associate with PV, PMF, post-ET myelofibrosis (PET-MF) and post-PV MF (PPV-MF), however significant overlap in allele burdens across these groups occurs. In MF, dominance by the neoplastic clone at the expense of wildtype precursors appears to be present in the majority of cases, indicating a dominant biology of the disease MPN clone at the stem cell level. (3) (4) (5) These clinical and molecular distinctions may reflect an intrinsic genetic complexity unique to primary and secondary MF compared to ET or PV.
The intrinsic genetic complexity in MF may have its basis in the acquisition of additional genomic lesions independent of JAK2 V617F, since 50% of cases are negative for the mutation. Acquired somatic mutations of the ASXL1 gene recently have been shown to be prevalent in many myeloid disorders, including acute myelogenous leukemia (AML), chronic myelomonocytic leukemia, and chronic myelogenous leukemia and myelodysplastic syndromes. (6) (7) (8) (9) (10) We examined the relationships of ASXL1 mutation or deletion in 166 MPN patients to both clinical phenotype and associated molecular features using both cross-sectional and longitudinal analyses. Table 1 ). The diagnosis of PV and ET were based on the Polycythemia Vera Study Group criteria (11, 12) or WHO criteria (13, 14) depending on the year of diagnosis; the diagnosis of PMF was based on Italian Consensus criteria (15) or WHO criteria (13) depending on the year of diagnosis. The study was approved by our Institutional Review Board and all patients gave written consent.
Design and Methods
Patients
Genomic Analysis DNA from neutrophils purified from peripheral blood samples was prepared as previously described.(16) Neutrophils were selected as the representative tumor tissue due to the observations that in the MPN, clonal dominance of the tumor is present at the neutrophil level, while polyclonal hematopoiesis may persist at the marrow progenitor level potentially diluting tumor DNA with DNA from residual wild type cells (3, 4) . The JAK2 V617F neutrophil allele burdens were measured using an allele-specific, quantitative real-time polymerase chain reaction (PCR) assay sensitive to a lower limit of detection of 5% of either the wild-type or mutant JAK2 allele as previously described. (4) Single nucleotide array karyotyping assay and analysis was performed as described previously. (17-19) Briefly, Gene Chip Mapping Affymetrix 250K arrays (Affymetrix, Santa Clara, CA, USA) were used for SNP-K analysis and utilized per the manufacturer's instructions. Signal intensity was analyzed and SNP calls determined using Gene Chip Genotyping Analysis Software Version 4.0 (GTYPE). Copy number (CN) and areas of UPD were investigated using a Hidden Markov Model and CN Analyzer for Affymetrix GeneChip Mapping 250K arrays (CNAG v3.0).
Direct PCR Sequencing Exon 12 of ASXL1 was amplified from neutrophil genomic DNA using PCR primers described by Gelsi-Boyer et al. 
Results
ASXL1 Sequence Variation in the MPN Cohort
We sequenced ASXL1 exon 12 in 77 MF, 42 PV, 41 ET and 6 post-MF AML patients ( Table 1) . JAK2
V617F-status and quantitative JAK2 V617F neutrophil allele burdens were determined for all patients and are presented in Table1, including 5 PV patients who were JAK2 V617F-negative, 4 of whom harbor JAK2 exon 12 mutations, and 1 of whom who is not molecularly defined. We found 28 nonsense lesions consisting of insertions, deletions or single nucleotide substitutions inducing stop lesions in 23 MF, 1 PV and none of the ET patients ( Tables 1 and 2 ). In 4 of the ASXL1-mutation-positive MF cases, more than one distinct ASXL1 mutation was identified (UPIN numbers 143, 376, 453 and 1327, Table 2 ). The distribution of the mutations across ASXL1 in this MPN cohort was similar to that reported in the Catalogue of Somatic Mutations in Cancer (http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=gene&ln=ASXL1) for a variety of hematologic diseases and in a large AML ASXL1 sequencing project(6) with the majority of lesions involving amino acids 591-888 ( Table 2) . Two recurrent lesions, 1934dupG and 1900_1922del, present in 8 38% (10/26) and 8% (2/26) respectively of the mutation positive MPN patients, were also the two most common lesions in the AML cohort(6), occurring in 66% and 7% of those patients, respectively. We found seven missense lesions in seven MPN patients, only three of which were reported as SNPs in dbSNP or 1000 Genomes Project (r3746609, rs35632616 and rs6057581, Table 3 ).
ASXL1 hemizygous deletion identified by SNP-K
We performed single nucleotide polymorphism array karyotyping (SNP-K) on neutrophil genomic DNA from all of the ET and PV patients (n=41 and 42, respectively), and from 67 of the 77 MF patients from the ASXL1 sequencing project (DNA was insufficient in 10 of the MF patients for SNP-K analysis).
Detailed results of this analysis are to be presented elsewhere (McDevitt, manuscript in preparation). Tables 1 and 2 ). The 20q deletion region was not otherwise involved by uniparental disomy or chromosomal gain in either the MF cases or the rest of the MPN SNP-K cohort. All MF cases in which the ASXL1 gene was affected by hemizygous deletion were resequenced and in none of these the remaining ASXL1 allele was affected by a nonsense lesion ( Table 2) .
ASXL1 Genotype/Phenotype Correlations in MF
We collected the clinical and molecular features of 73 of the 77 MF patients in which ASXL1 status was determined by direct sequencing and SNP-K. Four MF patients were censored from this analysis due to either incomplete clinical information (n=1) or due to their harboring missense lesions that are not reported as SNPs, whose effect on ASXL1 function is unknown (n=3; Table 3 ) and due to the fact that 9 suitable germline tissue to determine the somatic nature of these sequence variations was not available.
We thus compared 28 ASXL1 lesion positive MF patients (23 cases with ASXL1 nonsense lesions and 5 cases with ASXL1 hemizygous deletion, Table 2 ) to 45 MF patients with wild-type ASXL1 ( Table 4) .
ASXL1 deletion or mutation was equally prevalent in PMF (15/45, 33%), PPV-MF (5/14, 36%) and PET-MF (8/16, 50%, Table 4 ). ASXL1 lesions did not associate with chemotherapy exposure as the prevalence of hydroxyurea use was similar in patients with and without lesions, and ASXL1 lesions were present in patients who had never received any form of chemotherapy ( Table 4 ). There was no dependence upon JAK2 status as the presence of ASXL1 lesions was identified in JAK2 V617F-negative cases (9/28) (one patient of which harbored a JAK2 exon 12 lesion, H538K539delinsL, UPIN 1182, Table 2 ), JAK2 V617F-heterozygous cases (9/28), and JAK2 V617F-homozygous cases (10/28). Based on results of SNP-K, patients with ASXL1 lesions were equally as likely to have uniparental disomy (involving 9p or other regions), or chromosomal loss or gain abnormalities compared to those without ASXL1 lesions ( Table 4) .
There were no differences in sex, age, or disease duration between MF patients with and without ASXL1
lesions. Median white blood cell counts (10.7 vs. 12.5 x 10 9 /L; p=0.61), hemoglobin (9.9 vs. 11 g/dl;
p=0.25), and platelet counts (172 vs. 232 x 10 9 /L; p=0.45) did not differ between MF patients with and without ASXL1 lesions. However, those MF patients with ASXL1 lesions were more likely to have received anemia-directed therapy (transfusion, erythropoietin, immunomodulatory agents (thalidomide, steroids)) compared to those without lesions (15/28 (54%) vs. 11/45 (24%); p=0.023) ( Table 4) .
PET-MF comprised 28% (8/28) of ASXL1-lesion positive cases, compared to only 13% (6/45) ASXL1-wild type cases (p=0.11). Moreover, ASXL1 lesions were most prevalent in the PET-MF group, present in 8/16
individuals (Table 1) . However, the presence of an ASXL1 lesion did not associate with an accelerated transition rate from ET or PV to MF. In fact, the median time of transition from ET or PV to MF was longer in those with ASXL1 lesions compared to those without ASXL1 lesions (17 versus 9 years, 10 respectively in ET to MF, p=0.08; 20 vs. 9 years in PV to MF, p=0.16) but these differences were not statistically significant.
Six patients had AML at the time of ASXL1 analysis and 2/6 (33%) of these patients were found to have ASXL1 nonsense lesions (Tables 1 and 2 ). Eleven patients from remaining 160 MPN patients from this cohort ( Table 1) subsequently developed AML, 8 of whom were male, 10 of whom had antecedent MF and one of whom had PV ( Table 5 ). ASXL1 nonsense lesions were detected in the MPN phase of 4/10 of the PMF cases from this group, which was not different from the prevalence of ASXL1 nonsense lesions in the MF cohort at large or the AML cohort (23/77 and 2/6, respectively, Table 1 ). ASXL1 lesions were evident in the latent MPN phase as distant as 9 years before the development of AML (Table 5) .
Unfortunately, purified leukemic blasts were not available from any of the ASXL1-lesion positive patients for analysis.
Serial Analysis of ASXL1 mutation-positive cases
To test the relationship of ASXL1 lesions to MPN natural history, we determined whether mutations evident in granulocytes were consistently present in samples obtained at varying time points, and when possible, measured the ASXL1-mutant allele % using pyrosequencing based quantitative assays. In 2 ASXL1-mutation positive post-ET MF cases, we demonstrated the relationship of the ASXL1-mutant allele burden over sequential time points and its relationship to disease features and where relevant, JAK2 V617F allele burden (Figure 1) . These studies indicate that ASXL1 lesions associate with the transition of ET to MF, and increase over time independent of the JAK2 V617F allele burden (Figure 1 ).
The most common ASXL1 nonsense lesion, ASXL1 1934dupG, cannot be assessed using pyrosequencing assays due to its repetitive nucleotide sequence preceding the 1934 insertion. However, electropherograms generated from serial samples from a single patient indicate that ASXL1 1934dupG does also increase in intensity over time, analogous to other ASXL1 nonsense lesions (Supplemental 
Discussion
We found that disruption of the ASXL1 gene is prevalent in MF due to large 20q11 deletions that included the ASXL1 gene or due to acquired somatic mutation of ASXL1. ASXL1 lesions, either deletion or nonsense mutations, were present in 36% of MF cases, but were identified only rarely in ET or PV cases. In two cases, we demonstrated that ASXL1 mutations are clearly acquired, and appeared to accumulate in intensity over time as these patients progressed from ET to PET-MF. Since the residual allele was intact in the 5 cases in which ASXL1 was contained within the 20q deletion region, and the majority of ASXL1 lesions were nonsense lesions, it appears that ASXL1 haploinsufficiency may contribute to disease pathogenesis in primary and PET-MF or PPV-MF. With respect to clinical phenotype, ASXL1-lesion positive status correlated with a higher prevalence of anemia-directed therapy compared to MF patients that were ASXL1-wild-type. ASXL1 lesions were found in cases without exposure to chemotherapy (hydroxyurea), indicating that this is an acquired genetic event that is related to intrinsic genomic instability, and not a specific consequence of therapy-induced genomic damage. to an association of ASXL1 lesions to AML development in the current MPN series, ASXL1 lesions were no more prevalent in the patients who subsequently developed AML than in the MF patients as a whole, suggesting that ASXL1 does not directly cause a leukemic phenotype. ASXL1 lesions in both the AML cohort and this MPN cohort associated with older age and male sex ( Table 1) .
It has been suggested that the most commonly reported mutation within ASXL1, the 1934dupG frameshift lesion, is not a somatic alteration due to its detection paired tumor and buccal smears from MPN patients, and in its reported identification in individuals without myeloid disease(24). In our study and in the AML study, ASXL1 1934dupG was detected in disease phases but not remission phases in evaluable patients and we specifically show its acquisition and increasing intensity over sequential time In the context of the classical BCR-ABL-negative MPN, ASXL1 mutation or deletion implies a unique association with MF, an entity with a historically significantly shorter survival compared to ET or PV. We identified an association with a need for anemia-directed therapy (potentially associating with more severe anemia) in ASXL1-mutated patients, which often suggests a worse prognosis, given the significance of anemia to leukemic transformation and overall survival in MF.(2, 25-27) However, in our series, longer than median disease durations in patients with ASXL1 lesions argue against an association with a poor prognosis. Further, ASXL1 lesions did not appear to accelerate transformations from ET or PV to MF, did not accelerate transformations of MF to AML, and were not overrepresented in AML cases. In fact, deletions of 20q have been historically classified as "favorable." (28, 29) Given the wide range of natural history and survival even within MF(30) prospective studies with longer follow-up will be required in order to clarify any differences in prognosis between ASXL1 mutant and wild-type cases.
In conclusion, ASXL1 lesions are prevalent in MF and the association of these lesions, due to either mutation or deletion, suggests that ASXL1 haploinsufficiency is associated with a MF phenotype in the context of other known and unknown lesions, and that disruption of ASXL1 function may directly contribute to the pathophysiology and clinical complications of primary and secondary myelofibrosis.
These data support the concepts that cooperative lesions in addition to JAK2 V617F are critical in generating MF, that MF is molecularly more complex than either PV or ET, and that the transition of PV or ET to MF is associated with the acquisition of genomic lesions that are present in MF at large. Future studies testing the role of ASXL1 in murine models in combination with other myeloid lesions will be useful in determining its specific relationship to the pathophysiology of these disorders. The identification of ASXL1 as a prevalent, MF-specific disease allele within the MPN opens new pathways for diagnostic testing, disease monitoring (particularly ET to MF transition) and therapeutic targeting of epigenetic disregulation.
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